The FDA began taking the first step toward potentially changing how popular peptide products can be compounded in the US by convening advisors on whether a set of peptides should be allowed for compounding. The meeting is framed around whether the products meet safety criteria for compounding-category removal. This comes amid intense consumer demand for peptide injections favored by wellness influencers and athletes, and after prior FDA action under compounding pharmacy restrictions. FDA said it will ask outside advisers to review seven peptides, including BPC-157, with the question centered on whether they should be taken out of a restrictive category reserved for risky customized drugs. The policy process signals that regulators will increasingly scrutinize the safety evidence base behind high-volume, non-approved peptide use.